Progress of postmastectomy radiotherapy for axillary lymph node-negative breast cancer after neoadjuvant chemotherapy
10.3760/cma.j.cn115355-20210629-00282
- VernacularTitle:新辅助化疗后腋窝淋巴结阴性乳腺癌术后放疗的研究进展
- Author:
Li LIU
1
;
Qingyong XU
Author Information
1. 哈尔滨医科大学附属肿瘤医院乳腺放疗科，哈尔滨 150081
- Keywords:
Breast neoplasms;
Chemotherapy, adjuvant;
Radiotherapy;
Combined modality therapy
- From:
Cancer Research and Clinic
2022;34(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, neoadjuvant chemotherapy has been increasingly applied to the treatment of locally advanced or early-stage breast cancer patients, and has improved the pathological state and stage of the disease to a certain extent, which makes the decision-making of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients more complex. Existing guidelines have pointed out that patients with positive axillary lymph nodes after neoadjuvant chemotherapy are recommend for postmastectomy radiotherapy. However, postmastectomy radiotherapy is still controversial in patients with pathological complete remission or pathologically lymph node-negative after neoadjuvant chemotherapy. Radiotherapy can improve the local control rate and overall survival rate of patients, but some patients will have a series of adverse reactions after radiotherapy. Therefore, it is very important to find patients who can benefit from postmastectomy radiotherapy after neoadjuvant chemotherapy. This article reviews the research progress of postmastectomy radiotherapy for breast cancer patients with pathological complete remission or pathologically lymph node-negative after neoadjuvant chemotherapy.
